Search results for "HORMONE REPLACEMENT THERAPY"

showing 10 items of 72 documents

The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size

2001

Abstract Objectives: To disclose if oral estradiol (E 2 ), alone or in combination with natural progesterone (P) or medroxyprogesterone acetate (MPA), may modify the oxidizability of low density lipoprotein (LDL), and if the effect is achieved at physiological dosages. LDL oxidizability was assessed by the resistance to oxidation by copper and by the particle size profile, since small particles have increased oxidation susceptibility. Methods: Thirty-three women received two consecutive, two-month length doses of 1 and 2 mg/day of oral E 2 . They were then randomly assigned to a fourteen-day treatment of 2 mg/day E 2 plus either 300 mg/day P or 5 mg/day MPA. A parallel group of experiments …

medicine.medical_specialtyHormone Replacement Therapymedicine.drug_classMedroxyprogesteroneAdministration OralMedroxyprogesterone AcetateGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundHigh-density lipoproteinOral administrationInternal medicinemedicineHumansMedroxyprogesterone acetateParticle SizeProgesteroneDiminutionDose-Response Relationship DrugEstradiolbusiness.industryObstetrics and GynecologyCholesterol LDLMiddle AgedPostmenopauseEndocrinologychemistryEstrogenLow-density lipoproteinFemalelipids (amino acids peptides and proteins)businessOxidation-Reductionmedicine.drugLipoproteinMaturitas
researchProduct

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

2020

Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice. Methods: Given the spectrum of medications currently available and new insights into the understanding of AI, the authors reviewed relevant medical literature with emphasis on original studies, prospective observational data and randomized controlled trials performed in the past 35 years. The Expert Opinion of a panel of selected endocrinologists was sought to answer specific clinical questions. The objective was to provide an evidence-supported guide, for the use of GC in…

medicine.medical_specialtyHydrocortisoneHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlaw.inventionSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyGlucocorticoidRandomized controlled triallawPrednisonemedicineAdrenal insufficiencyOutpatient clinicHumansDosingIntensive care medicineGlucocorticoidsbusiness.industryAddison; Adrenal insufficiency; Cortisone acetate; Glucocorticoid; Hydrocortisone; Prednisonemedicine.diseaseItalyTransgender hormone therapyCortisone acetate030220 oncology & carcinogenesisPrednisoneObservational studybusinessMedical literaturemedicine.drugAddisonAdrenal InsufficiencyJournal of endocrinological investigation
researchProduct

Correlates of hormone replacement therapy use in Italian women, 1992-1996

1999

we analyzed the determinants of hormonal replacement therapy (HRT) use in Italy for the period 1992-1996, using data from a framework of case-control studies of colon and rectal neoplasm.a total of 1574 women aged 45-74 years were considered. This group comprised women with acute, non neoplastic, non-hormone-related diseases admitted to a network of hospitals in six areas of Italy.a total of 146 women (8.5%) reported ever HRT use. The multivariate odds ratio (OR) of ever use was 1.6 (95% CI 1.0-2.6) for women with 12 years of education or more, compared with those with7 years. The frequency of use of HRT tended to decrease with increasing parity: the OR was 0.6 for women with four or more c…

medicine.medical_specialtyNon neoplasticmenopauseGeneral Biochemistry Genetics and Molecular BiologyInternal medicineRectal NeoplasmmedicineHumansSocioeconomic statusAgedClimactericGynecologybusiness.industryEstrogen Replacement TherapyHormonal replacement therapyObstetrics and GynecologyOdds ratiocase control studyMiddle AgedPatient Acceptance of Health CareHormone replacement therapyItalyTransgender hormone therapyHormone replacement therapy; case control study; menopauseFemalebusinessHuman
researchProduct

The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention

2005

Hormone replacement therapy (HRT) has been reported to exert a positive effect on preserving muscle strength following the menopause, however, the mechanism of action remains unclear. We examined whether the mechanism involved preservation of muscle composition as determined by skeletal muscle attenuation. Eighty women aged 50-57 years were randomly assigned to either: HRT, exercise (Ex), HRT + exercise (ExHRT), and control (Co) for 1 year. The study was double-blinded with subjects receiving oestradiol and norethisterone acetate (Kliogest) or placebo. Exercise included progressive high-impact training for the lower limbs. Skeletal muscle attenuation in Hounsfield units (HU) was determined …

medicine.medical_specialtyPhysiologymedia_common.quotation_subjectAdipose tissuePhysical exerciseVertical jumpDouble-Blind MethodPhysiology (medical)Internal medicinemedicineHormone replacement therapy (male-to-female)Body SizeHumansMuscle SkeletalExerciseMenstrual cyclemedia_commonAnalysis of Variancebusiness.industryBody WeightEstrogen Replacement TherapySkeletal muscleGeneral MedicineMiddle Agedmedicine.diseaseNorethisterone acetatePostmenopauseMenopauseEndocrinologymedicine.anatomical_structureAdipose TissueFemaleTomography X-Ray Computedbusinessmedicine.drugClinical Physiology and Functional Imaging
researchProduct

Combination of hormone replacement therapy and high physical activity is associated with differences in Achilles tendon size in monozygotic female tw…

2009

Estrogen concentration has been suggested to play a role in tendon abnormalities and injury. In physically active postmenopausal women, hormone replacement therapy (HRT) has been suggested to decrease tendon diameter. We hypothesized that HRT use and physical activity are associated with Achilles tendon size and tissue structure. The study applied cotwin analysis of fourteen 54- to 62-yr-old identical female twin pairs with current discordance for HRT use for an average of 7 yr. Achilles tendon thickness and cross-sectional areas were determined by ultrasonography, and tendon structural organization was analyzed from the images using linear discriminant analysis (LDA). Maximal voluntary and…

medicine.medical_specialtyPhysiologymedicine.drug_classEstroneHormone Replacement TherapyAnterior cruciate ligamentPhysical activityMonozygotic twinPhysical exerciseMotor ActivityAchilles Tendon03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineSex Hormone-Binding GlobulinMedicineHumansTestosteroneMuscle StrengthAgedUltrasonographyAchilles tendonbusiness.industryEstrogens030229 sport sciencesTwins MonozygoticMiddle AgedTendonmedicine.anatomical_structureEndocrinologyCholesterolTransgender hormone therapyEstrogenFemaleMenopausebusiness030217 neurology & neurosurgeryMuscle ContractionJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Isolated erythema (cellulitis) of the breast.

2002

Abstract This paper reports nine cases of breast cellulitis in women patients (four cases in pregnancy, four postmenopausal cases following hormone replacement therapy and one case of unilateral breast oedema following a mediastinal lymphoma). Biopsies were obtained from the erythematous area in one pregnant patient, one postmenopausal patient and the patient with breast oedema associated with the mediastinal lymphoma. Histology revealed unspecific dermatitis with extensive perivascular lymphoplasmocellular infiltrates. Histopathological examination of biopsies obtained from the underlying mammary tissue along with the corresponding mammographic data gave no evidence of mastitis or mammary …

medicine.medical_specialtyPregnancyIntertrigoErythemabusiness.industrymedicine.medical_treatmentHormone replacement therapy (menopause)General Medicinemedicine.diseaseDermatologyMastitisSurgeryBreast cancerMediastinal LymphomaEtiologymedicineSurgerymedicine.symptombusinessBreast (Edinburgh, Scotland)
researchProduct

Determinants of adherence to osteoporosis treatment in clinical practice.

2006

Introduction: Poor adherence to prescribed treatments is widespread in clinical practice and this can lead to potentially life-threatening events. This problem is apparently very common for osteoporosis treatment but the causes of discontinuation and low compliance are complex and poorly defined. Methods: Global adherence to osteoporosis treatment was specifically addressed in a nation-wide survey carried out in 9851 postmenopausal women referred to 141 Italian centres for osteoporosis management for a follow-up assessment, at least one year after having been prescribed a treatment with one of the following drugs: calcium±vitamin D supplements alone (CaVitD), hormone replacement therapy (HR…

medicine.medical_specialtySettore MED/09 - Medicina InternaHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisosteoporosis; Determinants; Treatment adherence; Treatmentadherence; compliance; osteoporosis; persistence; treatmentInternal medicinemedicineTreatment adherenceHumansRaloxifeneDosingVitamin DDeterminantsOsteoporosis PostmenopausalAgedAdherence Compliance Osteoporosis Persistence TreatmentBone Density Conservation Agentsbusiness.industryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseosteoporosisRheumatologyDiscontinuationMenopauseTreatmentItalyOrthopedic surgeryPhysical therapyPatient ComplianceCalciumFemalebusinessmedicine.drugOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
researchProduct

Influence of long-term postmenopausal hormone-replacement therapy on estimated structural bone strength: A study in discordant monozygotic twins

2010

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft,…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentDentistryMonozygotic twin030209 endocrinology & metabolismBone and Bones03 medical and health sciences0302 clinical medicineBone strengthBone DensitymedicineHumansPostmenopausal Hormone Replacement TherapyOrthopedics and Sports Medicineta315Aged030304 developmental biologyBone mineral0303 health sciencesPostmenopausal womenAnthropometrybusiness.industryEstrogen Replacement Therapyta3141Hormone replacement therapy (menopause)Organ SizeTwins Monozygoticta3142Middle AgedHormonesConfidence intervalSurgerymedicine.anatomical_structureBody CompositionFemaleCortical boneDiaphysesSelf ReportbusinessJournal of Bone and Mineral Research
researchProduct

Hormone Replacement Therapy Associated White Blood Cell DNA Methylation and Gene Expression are Associated With Within-Pair Differences of Body Adipo…

2015

The loss of estrogen during menopause causes changes in the female body, with wide-ranging effects on health. Estrogen-containing hormone replacement therapy (HRT) leads to a relief of typical menopausal symptoms, benefits bone and muscle health, and is associated with tissue-specific gene expression profiles. As gene expression is controlled by epigenetic factors (including DNA methylation), many of which are environmentally sensitive, it is plausible that at least part of the HRT-associated gene expression is due to changes in DNA methylation profile. We investigated genome-wide DNA methylation and gene expression patterns of white blood cells (WBCs) and their associations with body compo…

medicine.medical_specialtyvaihdevuodetmedicine.drug_classHormone Replacement TherapyHRTmenopauseGene ExpressionBiologyBody fat percentageepigenetic regulationBody Mass IndexBone DensityInternal medicineGene expressionmedicineLeukocytesHumansgeeniekspressioEpigeneticsGeneGenetics (clinical)kehonkoostumusAdipositybody compositionta1184skeletal muscle compositionObstetrics and Gynecologyta3141DNA MethylationDNA-metylaatio3. Good healthPostmenopausehormone replacement therapyEndocrinologyDifferentially methylated regionsEstrogenPediatrics Perinatology and Child HealthDNA methylationLean body massFemalediscordant monozygotic twin pair designbone mineral contentGenome-Wide Association StudyTwin research and human genetics : the official journal of the International Society for Twin Studies
researchProduct

Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database.

2020

Purpose: To survey risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) practice and advice regarding hormone replacement therapy (HRT) in women with Lynch syndrome. Methods: We conducted a survey in 31 contributing centers from the Prospective Lynch Syndrome Database (PLSD), which incorporates 18 countries worldwide. The survey covered local policies for risk-reducing hysterectomy and BSO in Lynch syndrome, the timing when these measures are offered, the involvement of stakeholders and advice regarding HRT. Results: Risk-reducing hysterectomy and BSO are offered to path_MLH1 and path_MSH2 carriers in 20/21 (95%) contributing centers, to path_MSH6 carriers in 19/21 (91%) and…

medicine.medical_treatmentCàncer d'ovarilcsh:Medicinecomputer.software_genreleikkaushoitoCOLORECTAL-CANCER0302 clinical medicineHormone replacement therapy (female-to-male)munasarjasyöpäMalalties hereditàriesGynecological surgery030219 obstetrics & reproductive medicineManchester Cancer Research CentreDatabaseBrief ReportGeneral MedicineLynch syndrome3. Good healthESTROGENkohdunrungon syöpägynekologiset syövätovarian cancer030220 oncology & carcinogenesisendometrial cancerhormonihoitosyöpätauditHEALTHGenetic disordersGenetic counseling3122 Cancersehkäisevä lääketiede03 medical and health sciencesmedicinerisk-reducing surgeryMedical prescriptionLynchin oireyhtymäperinnölliset tauditHysterectomybusiness.industryResearchInstitutes_Networks_Beacons/mcrcHORMONE REPLACEMENT THERAPYEndometrial cancerlcsh:RInternational survey3126 Surgery anesthesiology intensive care radiologymedicine.diseaseLynch syndromeCàncer d'endometririsk reducing surgerybusinesscomputer
researchProduct